<DOC>
	<DOC>NCT00839423</DOC>
	<brief_summary>The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).</brief_summary>
	<brief_title>Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>MDE as primary diagnosis according to DSMIVTR criteria (classification code 296.xx) Current MDE duration of at least 3 months and less than 12 months The patient has a MADRS total score &gt;=30 Any current psychiatric disorder other than MDD as defined in the DSMIV TR Any substance disorder within the previous 6 months Female patients of childbearing potential who are not using effective contraception Use of any psychoactive medication 2 weeks prior to screening and during the study Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Major depressive disorder</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Active reference</keyword>
	<keyword>Multicenter study</keyword>
	<keyword>Randomised study</keyword>
	<keyword>Acute treatment</keyword>
</DOC>